NASDAQ · PRME
Healthcare · Biotechnology
$3.14
Down-$0.04 (-1.26%)
Updated Sep 16, 2026, 10:52 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PRME closed at $3.14 after 20 trading sessions, up 2.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.18 | $3.22 | $3.00 | $3.14 | 2.57M |
| Sep 14, 2026 | $3.10 | $3.28 | $3.10 | $3.18 | 1.62M |
| Sep 11, 2026 | $3.38 | $3.44 | $3.10 | $3.13 | 3.08M |
| Sep 10, 2026 | $3.37 | $3.42 | $3.31 | $3.35 | 2.39M |
| Sep 9, 2026 | $3.47 | $3.535 | $3.29 | $3.47 | 4.23M |
| Sep 8, 2026 | $3.65 | $3.65 | $3.41 | $3.56 | 3.6M |
| Sep 4, 2026 | $3.83 | $3.86 | $3.65 | $3.70 | 1.62M |
| Sep 3, 2026 | $3.70 | $3.72 | $3.49 | $3.71 | 2.31M |
| Sep 2, 2026 | $3.50 | $3.705 | $3.47 | $3.67 | 2.47M |
| Sep 1, 2026 | $3.54 | $3.71 | $3.48 | $3.57 | 2.46M |
| Aug 31, 2026 | $3.54 | $3.635 | $3.4601 | $3.59 | 2.09M |
| Aug 28, 2026 | $3.57 | $3.70 | $3.48 | $3.61 | 2.69M |
| Aug 27, 2026 | $3.55 | $3.665 | $3.48 | $3.64 | 1.83M |
| Aug 26, 2026 | $3.66 | $3.66 | $3.435 | $3.58 | 1.95M |
| Aug 25, 2026 | $3.30 | $3.71 | $3.285 | $3.71 | 3.32M |
| Aug 24, 2026 | $3.38 | $3.40 | $3.195 | $3.25 | 2.27M |
| Aug 21, 2026 | $3.26 | $3.49 | $3.24 | $3.39 | 3.6M |
| Aug 20, 2026 | $3.43 | $3.50 | $3.20 | $3.24 | 3.8M |
| Aug 19, 2026 | $3.29 | $3.59 | $3.25 | $3.54 | 6.79M |
| Aug 18, 2026 | $3.10 | $3.1988 | $3.02 | $3.05 | 1.27M |
The latest Smart Investors Daily articles mentioning PRME.
PRME research
Company profile and research snapshot.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | Chardan Capital | Buy | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 29, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 12, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Yahoo · Feb 11, 2026
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha · Jan 14, 2026
Prime Medicine, Inc. (PRME) 44th Annual J.P.
Yahoo · Jan 7, 2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California. A live audio webcast of the pres
Yahoo · Dec 31, 2025
Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating and $6 price target. The firm highlighted that Prime Medicine is advancing one-and-done gene editing treatments for conditions with high unmet medical needs, specifically […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRME.
